Non-small cell lung cancer
Synthekine Inc. is active in oncology with a focus on non-small cell lung cancer, including advanced lung cancer and other related solid tumors.
- PD-L1-negative NSQ NSCLC
- First-line treatment
- Advanced lung cancer
The company’s clinical research in this area centers on therapeutic strategies for patients with lung cancer who have limited immunotherapy options.
Immuno-oncology
The sponsor’s research interests include immune-based cancer therapy for solid tumors, with particular attention to treatment approaches that engage the tumor microenvironment.
- Immune-mediated antitumor activity
- Combination cancer treatment
- Solid tumor immunotherapy
Its clinical program reflects interest in therapies designed to broaden the role of immune modulation in cancer care.
Combination therapy
Synthekine’s trial portfolio includes investigation of combination regimens in lung cancer, with emphasis on integrating investigational treatment with existing standard-of-care cancer therapy.
- Therapeutic combinations
- Standard treatment integration
- Frontline oncology care
This area highlights clinical interest in improving outcomes for patients receiving treatment for newly diagnosed advanced disease.
Solid tumor drug development
The sponsor is involved in pharmaceutical development for solid tumors, with a disease focus that extends beyond lung cancer to other advanced malignancies.
- Advanced malignancies
- Oncology therapeutics
- Clinical evaluation in cancer
Its research activity is centered on identifying treatment options for patients with difficult-to-treat cancers in the advanced setting.
